Investigating biomarkers to improve outcomes in early psychosis treatment
3/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
This study is looking at how certain biological signs and health details can help predict how young adults with early psychosis will do over time, so that doctors can create more personalized treatment plans to support their recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10887563 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific biological markers and clinical features can predict the outcomes of early psychosis in young adults. By analyzing data from patients receiving coordinated specialty care, the study aims to categorize individuals based on their unique biomarker profiles and track their progress over time. The goal is to enhance treatment planning by tailoring interventions to the predicted trajectories of each patient, ultimately improving recovery rates and functional outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are young adults aged 18-35 who are experiencing early symptoms of psychosis, including those with bipolar disorder or schizophrenia.
Not a fit: Patients outside the age range of 18-35 or those not experiencing early psychosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for individuals experiencing early psychosis.
How similar studies have performed: Previous research has shown promise in using biomarkers to predict outcomes in psychosis, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Pearlson, Godfrey D — Yale University
- Study coordinator: Pearlson, Godfrey D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.